Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
Sci Rep. 2021 Nov 17;11(1):22384. doi: 10.1038/s41598-021-00920-4.
SuperSelective primers, by virtue of their unique design, enable the selective exponential amplification of rare DNA fragments containing somatic mutations in the presence of abundant closely related wild-type DNA fragments. However, when a SuperSelective primer is used in conjunction with a conventional reverse primer, linear amplification of the abundant wild-type fragments occurs, and this may lead to a late arising signal that can be confused with the late arising signal from the rare mutant fragments. We have discovered that the use of a pair of SuperSelective primers, one specific for the target mutation in a plus strand, and the other specific for the same mutation in the complementary minus strand, but both possessing 3'-terminal nucleotides that are complementary to the mutation, significantly suppresses the linear amplification of the related wild-type sequence, and prevents the generation of false mutant sequences due to mis-incorporation by the DNA polymerase. As a consequence, the absence of mutant fragments in a sample does not give rise to a false-positive signal, and the presence of mutant fragments in a sample is clearly distinguishable as a true-positive signal. The use of SuperSelective primer pairs should enhance the sensitivity of multiplex PCR assays that identify and quantitate somatic mutations in liquid biopsies obtained from patients with cancer, thereby enabling the choice of a targeted therapy, the determination of its effectiveness over time, and the substitution of a more appropriate therapy as new mutations arise.
超选择性引物凭借其独特的设计,能够在存在大量密切相关的野生型 DNA 片段的情况下,选择性地对包含体细胞突变的稀有 DNA 片段进行指数扩增。然而,当使用超选择性引物与常规反向引物结合时,会发生大量野生型片段的线性扩增,这可能导致出现与稀有突变片段的晚期信号混淆的晚期信号。我们发现,使用一对超选择性引物,一条针对正链上的靶突变,另一条针对互补负链上的相同突变,但两者都具有与突变互补的 3'末端核苷酸,可显著抑制相关野生型序列的线性扩增,并防止由于 DNA 聚合酶的错误掺入而产生假突变序列。因此,样品中不存在突变片段不会产生假阳性信号,而样品中存在突变片段则可清晰地区分为真正的阳性信号。超选择性引物对的使用应该会提高在从癌症患者获得的液体活检中识别和定量体细胞突变的多重 PCR 检测的灵敏度,从而能够选择靶向治疗,确定其随时间推移的有效性,并在出现新突变时替代更合适的治疗方法。